Keywords: Small Animals, High-Field MRI, temozolomide , Glycolysis inhibitor, GBM
Motivation: To develop an alternate effective therapy for treating glioblastomas.
Goal(s): To assess metabolic changes as therapeutic indices of treatment response to Lonidamine (LND)and temozolomide (TMZ) against glioblastoma (GBM).
Approach: C57BL6 mice implanted with GL261 GBM cells were treated with saline or LND+TMZ. Metabolic changes were monitored using longitudinal MRS.
Results: Significant reductions in lactate, tCho/NAA, Lip+Lac/tCr and mI/tCr ratios, were observed post-treatment, suggesting early indicators of treatment response.
Impact: This combination therapy might be a suitable alternative for better treatment of glioblastomas.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords